BD and ten23 health® Team Up To Enhance Aseptic Manufacturing With RFID Technology

Becton, Dickinson and Company (BD), a prominent global player in medical technology, has joined forces with ten23 health, a preferred strategic contract development and manufacturing organisation (CDMO) known for its human-centric and sustainable approach, to innovate tracking for prefillable syringes (PFS) through RFID technology.

This partnership is set to pilot BD's RFID solution, which aims to enhance efficiency in manufacturing processes while ensuring individual unit traceability. The initiative will provide significant advantages to ten23 health and its clients, improving traceability throughout the entire manufacturing process and supply chain.

The innovative traceability system, known as BD iDFill™ Individual Prefillable Syringe Identification*, introduces RFID technology to each prefillable syringe (PFS) by embedding a unique serial number called the Container Unique Identifier (CUID). This CUID can be scanned at various points throughout the manufacturing workflow, including the filling, secondary packaging, and any additional assembly stages.

By associating the drug code, filling batch details, timestamps, and other pertinent information with the CUID, this solution ensures comprehensive traceability for each container. It supports a range of applications such as automated reconciliation, prevention of mix-ups, and management of investigations. Additionally, the system facilitates swift identification and tracking of individual units during production and thereafter.

By emphasising individual units rather than batches, BD iDFill™ enhances visibility and efficiency in the manufacturing process. Additionally, treating the primary container as a connector between distinct operations, such as filling and inspection, allows ten23 health to maximise the valuable insights from existing process data. This approach also paves the way for innovative manufacturing applications, both on-site and in broader contexts.

“BD iDFill™ aims to transform the way we approach quality and efficiency in the fill & finish process by extending the role of the PFS from a drug container to a digital enabler. We expect this innovation will harness the vast potential of data in manufacturing and bring a new level of transparency to the pharmaceutical fill & finish process,” stated Patrick Jeukenne, president of BD Medical - Pharmaceutical Systems. 

Hanns-Christian Mahler, CEO of ten23 health, said in a statement, “We are excited about this collaboration with BD, as it aligns perfectly with our commitment to innovation and quality. This new RFID-based traceability solution has the potential to further enhance our manufacturing processes and also provides significant benefits to our pharmaceutical customers by ensuring greater transparency and reducing risks,” added Andrea Allmendinger, CSO of ten23 health.